Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
$4.41
$1.35
$50.10
$3.66M1.04227,964 shs650,294 shs
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$4.16
+2.0%
$3.28
$2.01
$5.64
$271.42M1.521.21 million shs772,341 shs
Innate Pharma SA stock logo
IPHYF
Innate Pharma
$1.31
$1.57
$1.31
$1.95
$109.82M0.588 shsN/A
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
$1.02
-3.8%
$0.73
$0.37
$1.15
$242.06M1.61.60 million shs1.88 million shs
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$5.42
-1.8%
$3.98
$2.41
$10.37
$427.89M2.341.20 million shs1.29 million shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
0.00%0.00%0.00%0.00%-92.21%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
+1.96%+13.79%-3.26%+68.42%+88.24%
Innate Pharma SA stock logo
IPHYF
Innate Pharma
0.00%-32.82%-9.66%-9.66%-32.13%
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
-3.77%+0.99%+36.89%+117.11%+14.22%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-1.81%+8.92%+12.22%+100.74%-22.68%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
1.2629 of 5 stars
3.80.00.00.00.60.00.0
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
1.9149 of 5 stars
3.41.00.00.03.20.00.6
Innate Pharma SA stock logo
IPHYF
Innate Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
2.0429 of 5 stars
3.51.00.00.00.03.30.6
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.489 of 5 stars
4.62.00.00.02.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
3.50
Strong Buy$6.00∞ Upside
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2.83
Moderate Buy$11.70181.25% Upside
Innate Pharma SA stock logo
IPHYF
Innate Pharma
0.00
N/AN/AN/A
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
3.00
Buy$4.20311.76% Upside
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
3.17
Buy$15.10178.60% Upside

Current Analyst Ratings Breakdown

Latest APTO, SLDB, CRDF, LCTX, and IPHYF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
LADENBURG THALM/SH SH
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$19.00
6/26/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
6/26/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$14.00
6/24/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$3.50
6/23/2025
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$2.00
6/23/2025
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
6/18/2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
6/17/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/6/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$15.00
5/22/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$16.00
5/19/2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $15.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/AN/AN/AN/A($0.19) per shareN/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
$680K407.01N/AN/A$1.86 per share2.24
Innate Pharma SA stock logo
IPHYF
Innate Pharma
$21.77M5.04N/AN/A$0.11 per share11.91
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
$9.50M24.52N/AN/A$0.35 per share2.91
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
$8.09M51.93N/AN/A$3.43 per share1.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
-$51.21M-$89.19N/AN/AN/AN/A-5,683.22%-300.44%N/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$45.43M-$0.92N/AN/AN/A-8,308.50%-76.45%-62.85%8/14/2025 (Estimated)
Innate Pharma SA stock logo
IPHYF
Innate Pharma
-$53.53MN/A0.00N/AN/AN/AN/A9/17/2025 (Estimated)
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
-$18.61M-$0.12N/AN/AN/A-169.57%-22.64%-15.27%8/6/2025 (Estimated)
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$124.70M-$2.99N/AN/AN/AN/A-68.15%-55.33%8/12/2025 (Estimated)

Latest APTO, SLDB, CRDF, LCTX, and IPHYF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
-$0.53-$0.59-$0.06-$0.59N/AN/A
5/8/2025Q1 2025
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
-$0.19-$0.20-$0.01-$0.20$0.09 million$0.11 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/AN/AN/AN/AN/A
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/AN/AN/AN/AN/A
Innate Pharma SA stock logo
IPHYF
Innate Pharma
N/AN/AN/AN/AN/A
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
N/AN/AN/AN/AN/A
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
N/A
1.05
1.05
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
N/A
6.22
6.22
Innate Pharma SA stock logo
IPHYF
Innate Pharma
N/A
2.60
2.60
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
N/A
3.82
3.82
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
N/A
10.89
10.89

Institutional Ownership

CompanyInstitutional Ownership
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
26.62%
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
16.29%
Innate Pharma SA stock logo
IPHYF
Innate Pharma
N/A
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
62.47%
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
81.46%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aptose Biosciences Inc. stock logo
APTO
Aptose Biosciences
312.14 million63.45 millionNo Data
Cardiff Oncology, Inc. stock logo
CRDF
Cardiff Oncology
2066.53 million61.40 millionOptionable
Innate Pharma SA stock logo
IPHYF
Innate Pharma
17983.83 million57.10 millionNot Optionable
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
60228.36 million167.16 millionNot Optionable
Solid Biosciences Inc. stock logo
SLDB
Solid Biosciences
10077.51 million76.04 millionOptionable

Recent News About These Companies

SLDB Solid Biosciences Inc. - Seeking Alpha
Solid Biosciences Inc. (SLDB) - Yahoo Finance
SLDB - Solid Biosciences Inc Valuation - Morningstar
Solid Biosciences Inc. (SLDB) Cash Flow - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Aptose Biosciences stock logo

Aptose Biosciences NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Cardiff Oncology stock logo

Cardiff Oncology NASDAQ:CRDF

$4.16 +0.08 (+1.96%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$4.08 -0.08 (-1.80%)
As of 08:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Innate Pharma stock logo

Innate Pharma OTCMKTS:IPHYF

$1.31 0.00 (0.00%)
As of 07/9/2025

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.

Lineage Cell Therapeutics stock logo

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

$1.02 -0.04 (-3.77%)
Closing price 07/10/2025 04:10 PM Eastern
Extended Trading
$1.01 -0.01 (-0.49%)
As of 08:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Solid Biosciences stock logo

Solid Biosciences NASDAQ:SLDB

$5.42 -0.10 (-1.81%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$5.37 -0.05 (-0.90%)
As of 08:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.